Autolus Therapeutics Reports 118% Revenue Growth to $45.7 Million in Q2 2026

Autolus Therapeutics plc reported significant financial performance improvements in its latest quarterly filing, with total revenue reaching $45.7 million for the three months ended June 30, 2026, a substantial increase of 118% compared to $20.9 million in the same period last year. For the first half of 2026, the company generated $71.9 million in revenue, up 140% from $29.9 million in the first half of 2025. This growth was primarily driven by increased demand for its product AUCATZYL (obecabtagene autoleucel) in both the U.S. and U.K. markets, following its launch in the U.K. in January 2026.

Despite the revenue growth, Autolus reported a net loss of $39.1 million for the second quarter of 2026, a decrease from a loss of $47.9 million in the same quarter of 2025. The company’s accumulated deficit increased to $1.5 billion as of June 30, 2026, compared to $1.4 billion at the end of 2025. The loss from operations for the first half of 2026 was $103.4 million, down from $126.5 million in the prior year, indicating improved operational efficiency.

Operationally, Autolus has made strategic moves to enhance its market position, including a workforce reduction of approximately 13% aimed at improving efficiency and reducing costs. This restructuring is expected to save the company about $15 million annually starting in 2027. The company also announced a strategic financing agreement with Perceptive Advisors, which includes a $75 million initial drawdown from a $250 million credit facility, aimed at supporting ongoing operations and product commercialization efforts.

In terms of product adoption, Autolus has seen a notable increase in the number of doses administered of AUCATZYL, reflecting its growing acceptance among treatment centers. The company is also expanding its clinical trials, with ongoing studies for obe-cel in various conditions, including pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia and systemic lupus erythematosus. The company anticipates that these developments will further enhance its market presence and revenue potential.

Looking ahead, Autolus remains focused on advancing its clinical programs and expanding its commercialization efforts. The company expects to continue incurring significant expenses as it markets AUCATZYL and develops its pipeline of product candidates. Management believes that its current cash and cash equivalents, along with the recent financing, will be sufficient to fund operations for at least the next twelve months, although it acknowledges the need for additional capital to support its long-term growth objectives.